New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
04:55 EDTCGIX, CGIX, CGIX, HART, HART, HART, NURO, NURO, NURO, CANF, CANF, CANF, AMBS, AMBS, AMBS, AGEN, AGEN, AGEN, AVXL, AVXL, AVXL, SYN, SYN, SYN, CEMI, CEMI, CEMI, SRNE, SRNE, SRNE, OXBT, OXBT, OXBTOneMedPlace to hold a forum
7th Annual OneMedForum SF 2014 is being held in San Francisco on January 13-15.
News For CGIX;SRNE;CEMI;SYN;AVXL;AGEN;AMBS;CANF;NURO;HART;OXBT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
08:51 EDTCEMIChembio Diagnostics signs agreement with CDC contractor for flu test
Subscribe for More Information
06:59 EDTSYNSynthetic Biologics to initiate clinical trials of SYN-004
Synthetic Biologics announced that its Investigational New Drug, or IND, application which was submitted to the FDA in October will be proceeding into clinical trials for the development of the Company's oral beta-lactamase enzyme SYN-004 for the prevention of Clostridium difficile, or C. difficile, infection, antibiotic-associated diarrhea, and secondary infections with healthcare-acquired, drug-resistant pathogens in patients receiving intravenous beta-lactam antibiotic therapy. Synthetic Biologics plans to begin Phase 1a and 1b clinical trials shortly, with topline data expected to be reported before year-end. Synthetic Biologics has met each milestone for its C. difficile program leading up to the IND submission to the agency. Clinical drug manufacturing of SYN-004 under cGMP guidelines to support Synthetic Biologics' planned Phase 1 and 2 clinical trials was completed on time to support the IND submission and clinical trial initiation. Most recently, the U.S. Patent and Trademark Office issued a Notice of Allowance for the first composition of matter patent application directly pertaining to SYN-004 in the U.S., which carries a patent term to at least 2031.
November 18, 2014
08:45 EDTCANFCan-Fite BioPharma CF101 has major catalysts, says Roth Capital
Subscribe for More Information
07:14 EDTCANFCan-Fite BioPharma initiated with a Buy at H.C. Wainwright
Subscribe for More Information
07:08 EDTCANFCan-Fite BioPharma sees announcing data for Phase II/III psoriasis trial in 1Q15
Can-Fite BioPharma announced several upcoming and near-term milestones on its CF101 and CF102 indications for liver cancer, rheumatoid arthritis, psoriasis, glaucoma and the development of a commercial biomarker blood test kit for the A3 adenosine receptor. For Q4, the company is planning Phase III trials for CF101 for rheumatoid arthritis following the release of positive Phase II study results. Also in Q4, for CF102, patient enrollment has commenced for a Phase II trial in Israel, Europe and the U.S. for the treatment of patients with advanced liver cancer as a second line therapy. In 1Q15, for CF101, the company plans to announce data for Phase II/III trial for psoriasis with 300 patients for which Can-Fite has already received positive interim data from the first 100 patients. Also for CF101, in Q2/Q3 2015, the company plans to announce data for the Phase II study for glaucoma with 88 patients.
November 17, 2014
12:09 EDTAMBSAmarantus Bioscience to host business news update conference call
Subscribe for More Information
November 14, 2014
06:57 EDTSYNSynthetic Biologics reports Q3 EPS (8c), consensus (5c)
Subscribe for More Information
November 13, 2014
07:19 EDTAVXLCNS Summit to hold a summit
Subscribe for More Information
November 12, 2014
08:12 EDTAVXLSeeThruEquity to hold a conference
Subscribe for More Information
07:22 EDTCGIXAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
07:56 EDTCGIXCancer Genetics receives second patent for FHACT
Cancer Genetics announced that it has received a second U.S. patent covering its proprietary FISH-based HPV-Associated Cancer Test, or FHACT, for cervical cancer detection in patients. FHACT is designed to assess change across four biomarkers indicating HPV-associated pre-cancers and cancers. Critically, FHACT can help prevent unnecessary colposcopies and cervical biopsies, reducing costs and complications associated with these invasive procedures.
November 10, 2014
07:58 EDTCGIXCancer Genetics reports adjusted Q3 EPS (41c), consensus (48c)
Reports Q3 revenue $3.22M, consensus $3.18M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use